Cost-Effective Gastric Cancer Prevention with Co-Testing in Taiwan: A JAMA Analysis

💬 Editor's Note by JAMA Associate Editor John Inadomi, MD: Decision and cost-effectiveness analyses extend the impact of randomized clinical trials by enabling quantitative comparisons of competing strategies under real-world conditions, including resource use, costs, and long-term health outcomes.

In the analysis accompanying the trial by Lee et al, combining Helicobacter pylori stool antigen testing with fecal immunochemical testing (#FIT) was not only cost-effective but also cost-saving for gastric cancer prevention in Taiwan.

The value of co-testing is highly dependent on H pylori prevalence and eradication rates, with cost-effectiveness thresholds varying by region and health system costs. These findings emphasize the utility of decision analysis in guiding policy and the adoption of preventive strategies based on local epidemiology and resource parameters.

https://ja.ma/4dQEsRm